Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy. Issue 1 (January 2013)
- Record Type:
- Journal Article
- Title:
- Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy. Issue 1 (January 2013)
- Main Title:
- Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy
- Authors:
- Zheng, Lu
Bosch, Ronald J
Chan, Ellen S
Read, Sarah
Kearney, Mary
Margolis, David M
Mellors, John W
Eron, Joseph J
Gandhi, Rajesh T - Other Names:
- Leavitt Randi non-byline-author.
Coffin John non-byline-author.
Palmer Sarah non-byline-author.
Pettinelli Carla non-byline-author.
Martinez Ana non-byline-author.
Demeter Lisa M non-byline-author.
Jacobson Jeffrey M non-byline-author.
D'Aquila Richard non-byline-author.
Philpotts Barbara non-byline-author.
Donoval Betty A non-byline-author.
Levaro Robert non-byline-author. - Abstract:
- Background: HIV-1-infected individuals with plasma RNA<50 copies/ml on antiretroviral therapy (ART) may have residual, low-level viraemia detectable by PCR assays that are able to detect a single copy of viral RNA (single-copy assay [SCA]). The clinical predictors of residual viraemia in patients on long-term suppressive ART are not yet fully understood. Methods: We evaluated factors associated with residual viraemia in patients on suppressive ART who underwent screening for a raltegravir intensification trial (ACTG A5244). The screened population was HIV-1-infected adults receiving ART for ≥12 months with pre-ART HIV-1 RNA>100, 000 copies/ml and on-therapy RNA levels below detection limits of commercial assays for ≥6 months. Results: Of 103 patients eligible for analysis, the median age was 46 years and the median duration of viral suppression was 4.8 years. 62% had detectable viraemia (>0.2 copies/ml) by SCA (median 0.2 copies/ml, IQR <0.2–1.8). Younger patients had lower HIV-1 RNA levels than older individuals (r=0.27, P =0.005). Patients with virological suppression on ART for 2 years or less had higher residual viraemia than those with suppression for >2 years (median 2.3 versus 0.2 copies/ml; P =0.016). Conclusions: Among HIV-1-infected patients with pre-ART HIV-1 RNA>100, 000 copies/ml, residual viraemia was detectable in the majority (62%) despite many years of suppressive ART. Higher level viraemia was associated with older age and <2 years of virologicalBackground: HIV-1-infected individuals with plasma RNA<50 copies/ml on antiretroviral therapy (ART) may have residual, low-level viraemia detectable by PCR assays that are able to detect a single copy of viral RNA (single-copy assay [SCA]). The clinical predictors of residual viraemia in patients on long-term suppressive ART are not yet fully understood. Methods: We evaluated factors associated with residual viraemia in patients on suppressive ART who underwent screening for a raltegravir intensification trial (ACTG A5244). The screened population was HIV-1-infected adults receiving ART for ≥12 months with pre-ART HIV-1 RNA>100, 000 copies/ml and on-therapy RNA levels below detection limits of commercial assays for ≥6 months. Results: Of 103 patients eligible for analysis, the median age was 46 years and the median duration of viral suppression was 4.8 years. 62% had detectable viraemia (>0.2 copies/ml) by SCA (median 0.2 copies/ml, IQR <0.2–1.8). Younger patients had lower HIV-1 RNA levels than older individuals (r=0.27, P =0.005). Patients with virological suppression on ART for 2 years or less had higher residual viraemia than those with suppression for >2 years (median 2.3 versus 0.2 copies/ml; P =0.016). Conclusions: Among HIV-1-infected patients with pre-ART HIV-1 RNA>100, 000 copies/ml, residual viraemia was detectable in the majority (62%) despite many years of suppressive ART. Higher level viraemia was associated with older age and <2 years of virological suppression on ART. These findings should help in the selection of candidates for clinical trials of interventions designed to eliminate residual viraemia. … (more)
- Is Part Of:
- Antiviral therapy. Volume 18:Issue 1(2013)
- Journal:
- Antiviral therapy
- Issue:
- Volume 18:Issue 1(2013)
- Issue Display:
- Volume 18, Issue 1 (2013)
- Year:
- 2013
- Volume:
- 18
- Issue:
- 1
- Issue Sort Value:
- 2013-0018-0001-0000
- Page Start:
- 39
- Page End:
- 43
- Publication Date:
- 2013-01
- Subjects:
- Antiviral agents -- Periodicals
Antiviral Agents -- therapeutic use
Virus Diseases -- therapy
Viruses -- drug effects
Antiviral agents
Periodical
Electronic journals
Periodicals
616.9106 - Journal URLs:
- http://www.intmedpress.com/General/showSectionSub.cfm?SectionID=2&SectionSubID=1&SectionSubSubID=1 ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.3851/IMP2323 ↗
- Languages:
- English
- ISSNs:
- 1359-6535
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24494.xml